흡입제 시장 예측(-2030년) : 의약품 종류별, 유통 채널별, 용도별, 지역별 세계 분석

According to Stratistics MRC, the Global Inhalable Drugs Market is accounted for $34.3 billion in 2023 and is expected to reach $61.9 billion by 2030 growing at a CAGR of 8.8% during the forecast period. The inhalable drugs market encompasses pharmaceutical products delivered through inhalation routes, targeting respiratory conditions or systemic diseases. Inhalable drugs are administered directly to the respiratory system, allowing for rapid absorption into the bloodstream and localized therapeutic effects. The inhalable drugs market serves as a vital avenue in modern medicine, offering innovative solutions for the treatment of various respiratory diseases and systemic conditions. Inhalable drugs, administered through inhalers or nebulizers, provide rapid and targeted delivery directly to the respiratory system, ensuring efficient absorption and onset of action.

According to the Centers for Disease Control and Prevention (CDC), more than 25 million people had asthma in the U.S. in 2021, accounting for approximately 8.0% of adults and 6.5% of children. According to an article released by the World Health Organization in October 2022, globally, the percentage of individuals aged 60 years and above is likely to increase twofold from 12% in 2015 to 22% by 2050.

Market Dynamics:

Driver:

Rising prevalence of respiratory diseases

The increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis has spurred significant growth in the inhalable drugs market. As these conditions become more prevalent globally, the demand for effective treatment options has escalated. Inhalable drugs offer several advantages over traditional oral medications, including targeted delivery directly to the lungs, rapid onset of action, and reduced systemic side effects. Additionally, advancements in inhalation technology have led to the development of innovative delivery devices, improving patient convenience and adherence to treatment regimens.

Restraint:

Risk of misusing inhalable medications

Inhalers can be misused intentionally for recreational purposes or unintentionally due to improper administration techniques. There's a potential for abuse, particularly with medications that have psychoactive effects. Such misuse not only compromises the effectiveness of the treatment but also raises concerns regarding patient safety and regulatory compliance. Consequently, healthcare providers and regulatory agencies emphasize stringent monitoring and education to mitigate the risk of misuse, which can potentially limit the market's expansion.

Opportunity:

Possibility of inhaling biologics delivery

The emergence of inhalable biologics delivery has significantly bolstered the Inhalable Drugs Market by offering a more efficient and patient-friendly administration method. Biologics, which are large molecules derived from living organisms, have revolutionized the treatment landscape for various chronic conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. The possibility of inhaling biologics presents a non-invasive, needle-free alternative, allowing for direct delivery to the lungs where many respiratory diseases originate. This not only enhances patient comfort and adherence but also potentially improves therapeutic outcomes through targeted delivery and reduced systemic side effects.

Threat:

High development costs

High development costs act as a significant barrier in the inhalable drugs market, impeding innovation and the introduction of new products. The intricate process of developing inhalable drugs involves extensive research, clinical trials, and regulatory approvals, all of which incur substantial expenses. Pharmaceutical companies often face the challenge of balancing these high costs with potential market demand and profitability. However, the complexity of inhalable drug delivery systems necessitates sophisticated technologies and expertise, further contributing to elevated development expenses.

Covid-19 Impact:

With the respiratory nature of the virus, there was an increased focus on respiratory drug delivery systems, driving demand for inhalable drugs. The need for effective treatments for Covid-19 symptoms, such as respiratory distress, led to a surge in research and development of inhalable medications. Lockdowns and social distancing measures disrupted the supply chain and distribution networks, causing temporary setbacks in production and distribution. Healthcare systems prioritized Covid-19 management, diverting attention and resources away from other medical conditions, including respiratory diseases typically treated with inhalable drugs.

The leukotriene modifiers segment is expected to be the largest during the forecast period

Leukotriene Modifiers segment is expected to be the largest during the forecast period. By targeting the inflammatory pathway mediated by leukotrienes, these medications offer a novel approach to managing respiratory conditions, particularly asthma, which affects millions worldwide. Unlike traditional bronchodilators, leukotriene modifiers work by inhibiting the production or action of leukotrienes, thereby reducing airway inflammation and constriction. This mechanism not only provides symptom relief but also helps in preventing asthma exacerbations and improving overall lung function.

The retail pharmacies segment is expected to have the highest CAGR during the forecast period

Retail Pharmacies segment is expected to have the highest CAGR during the forecast period as these pharmacies serve as accessible points of distribution, making inhalable drugs readily available to consumers. With the increasing prevalence of respiratory ailments like asthma and COPD, the convenience of obtaining inhalable medications from nearby pharmacies significantly improves patient adherence to treatment regimens. Moreover, retail pharmacies often offer patient education and counseling services, aiding in proper inhaler technique and medication management. Furthermore, retail pharmacies serve as hubs for innovation, stocking new inhalable drug formulations and delivery devices, thus driving market growth by catering to evolving patient needs and preferences.

Region with largest share:

Asia Pacific region is expected to hold the largest share of the market over the projected period. As countries in the region invest more in healthcare infrastructure and services, there is an increased focus on innovative drug delivery systems, including inhalable drugs. The growing middle-class population and changing lifestyles contribute to the rise in respiratory disorders, further driving the demand for inhalable drugs in the region. With healthcare spending continuing to surge in Asia Pacific, pharmaceutical companies are increasingly investing in research and development of inhalable drug formulations, thus propelling the growth of the inhalable drugs market in the region.

Region with highest CAGR:

Asia Pacific region is estimated to witness profitable growth during the extrapolated period. Government regulations in the Asia Pacific region have played a substantial role in enhancing the Inhalable Drugs Market by fostering a favorable environment for innovation, safety, and accessibility. Regulatory frameworks, such as the approval processes for drug registration and manufacturing standards, ensure that inhalable drugs meet stringent quality and efficacy standards before entering the market. As a result, government regulations have not only safeguarded public health but also catalyzed the growth of the inhalable drugs market in the Asia Pacific region.

Key players in the market

Some of the key players in Inhalable Drugs market include AstraZeneca, Boehringer Ingelheim International GmbH, Cipla Inc, GlaxoSmithKline plc, Merck & Co., Inc, Mundipharma International, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd and Viatris Inc.

Key Developments:

In November 2023, Sanofi, a pharmaceutical company, announced that Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating U.S. Food and Drug Administration submission and confirming potential to become first approved biologic for this serious disease

In July 2023, Viatris Inc., a global healthcare company, and Kindeva Drug Delivery L.P., a pharmaceutical contract development and manufacturing organization, launched Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first generic version of AstraZeneca's Symbicort with an abbreviated new drug application (ANDA) approved by the U.S. Food and Drug Administration (FDA).

In January 2023, AstraZeneca received approval from the U.S. Food and Drug Administration for Airsupra (albuterol and budesonide) inhalation aerosol. Airsupra aims to reduce the risk of asthma exacerbations in individuals aged 18 years and older.

In November 2022, PT027 had been recommended by the U.S.FDA Advisory Committee as new rescue treatment for asthma. T027 is a potential first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication in the U.S. containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS). It is being developed by AstraZeneca, a pharmaceutical company and Avillion, a global drug development company.

In March 2022, Viatris Inc. and Kindeva Drug Delivery L.P. received FDA approval for Breyna, a drug-device combination therapy recommended for patients with asthma or chronic obstructive pulmonary disease (COPD).

Drug Classes Covered:

• Long-acting Beta Antagonists (LABAs)
• Inhaled Corticosteroids
• Long-acting Muscarinic Antagonists (LAMAs)
• Leukotriene Modifiers
• Other Drug Classes

Distribution Channels Covered:

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies
• Other Distribution Channels

Applications Covered:

• Non-respiratory Diseases
• Respiratory Diseases
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Inhalable Drugs Market, By Drug Class

• 5.1 Introduction
• 5.2 Long-acting Beta Antagonists (LABAs)
• 5.3 Inhaled Corticosteroids
• 5.4 Long-acting Muscarinic Antagonists (LAMAs)
• 5.5 Leukotriene Modifiers
• 5.6 Other Drug Classes

6 Global Inhalable Drugs Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Online Pharmacies
• 6.3 Retail Pharmacies
• 6.4 Hospital Pharmacies
• 6.5 Other Distribution Channels

7 Global Inhalable Drugs Market, By Application

• 7.1 Introduction
• 7.2 Non-respiratory Diseases
• 7.3 Respiratory Diseases
• 7.4 Other Applications

8 Global Inhalable Drugs Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 AstraZeneca
• 10.2 Boehringer Ingelheim International GmbH
• 10.3 Cipla Inc
• 10.4 GlaxoSmithKline plc
• 10.5 Merck & Co., Inc
• 10.6 Mundipharma International
• 10.7 Novartis International AG
• 10.8 Pfizer Inc
• 10.9 Teva Pharmaceutical Industries Ltd
• 10.10 Vectura Group Ltd
• 10.11 Viatris Inc